Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD

It is a prospective, multicenter, randomized controlled trial to investigate the predictive value of MRD on adjuvant therapy. Stage IA2-II resected NSCLC patients will undergo two-round MRD tests after surgery, first in 3-7 days and second in 1 month after surgery. And patients who confirm two-round landmark undetectable MRD will be enrolled and randomly assigned to the conventional treatment group or the adaptive therapy group . Patients in the the adaptive therapy group will undergo closely MRD and imaging monitoring without adjuvant therapy if the MRD was negative.

NCT Number	NCT06924710
Lead Sponsor	Peking University Cancer Hospital & Institute Collaborators: Tianjin Chest Hospital, Peking University First Hospital, Bethune First Hospital of Jilin University, Beijing Friendship Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Liaoning Cancer Hospital & Institute, Geneplus-Beijing Co. Ltd.
Conditions	NSCLC
Enrollment	286 participants
Start Date	2025-04-06
Primary Completion	2029-06-15 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-10-02